Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.
Enabling Technology Supports the Development of Anocca’s Deep Pipeline of TCR-T therapeutics
New York, USA, & Södertälje, Sweden, 14th March 2024 –Anocca AB (Anocca), a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, and EmendoBio Inc. (EmendoBio), a nuclease discovery and gene editing therapeutics company, today announced a non-exclusive licensing agreement for the use of EmendoBio’s novel OMNI-A4 nuclease to accelerate the manufacture and development of Anocca’s deep pipeline of TCR-T cell therapies for difficult-to-treat solid cancers.
